Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2010
08/25/2010CN101322737B Persimmon leaf flavones extract and preparation thereof
08/25/2010CN101264199B Medicaments for treating ischemic apoplexy sequela
08/25/2010CN101210011B Quinolines compounds and their intermediates, preparation method and application
08/25/2010CN101143845B Substituted quinoline formyl guanidine derivative, its preparation method and medical use
08/25/2010CN101108252B Pharmaceutical composition of cyclodextrin dragon's blood and method of preparing the same
08/25/2010CN101044908B High nutrition product developed from vertebra bone of freshwater eel
08/25/2010CN101044902B Health-care product for reducing weight and lowering cholesterin content in blood
08/25/2010CN101041626B Tetrafluorobenzyl derivatives and pharmaceutical composition containing same
08/24/2010US7781596 Substituted 2-phenylbenzimidazoles, the production thereof and their use
08/24/2010US7781487 N-(1-cyanocyclopropyl)-4,4-difluoro-2(S)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino)octamide; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, psoriasis, pemphigus vulgaris, Graves' disease, myasthenia gravis, lupus, asthma, pain, atherosclerosis; cathepsins B, K, L, F, and S inhibitors
08/24/2010US7781470 Aminodicarboxylic acid derivatives having pharmaceutical properties
08/24/2010US7781468 peroxisome proliferator-activated receptor (PPAR) agonists such as (2S)-3-{-4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)-ethoxy]-phenyl}-2-(3-phenyl-acryloylamino)-propionic acid, used for the treatment of hyperglycemia, dyslipidemia, non-insulin dependent diabetes and hyperlipemia
08/24/2010US7781463 Enzyme inhibitors
08/24/2010US7781450 protein kinase C or glycogen synthase kinase-3-beta inhibitors such as 3-(2-chlorophenyl)-4-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-1H-pyrrole-2,5-dione, used for treating cardiovascular, skin, nervous system disorders and immunological disorders, diabetes, inflammatory diseases and cancer
08/24/2010US7781440 Neurodegenerative diseases caused by GSK3 such as Alzheimer's disease
08/24/2010US7781428 Pyrazoline compounds
08/24/2010US7780953 Based on iron oxide, complexed by gem-bisphosphonate compounds, coupled to biovector (protein); colloids; peptization; for use as contrast agents for magnetic resonance imaging; labelling stem cells
08/24/2010CA2582049C Bilayer tablet comprising telmisartan and amlodipine
08/24/2010CA2517205C Process for preparation of perindopril and salts thereof
08/24/2010CA2507749C Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
08/24/2010CA2467857C Piperidine-based mch antagonists for treatment of obesity and cns disorders
08/24/2010CA2464906C Improved endoprosthetic device
08/24/2010CA2460135C Use of pyridazinone compounds as phosphodiesterase iv inhibitors for treating cancer and other diseases
08/24/2010CA2423103C N-acylsulfonamide apoptosis promoters
08/24/2010CA2391915C 3-phenyl-3,7-diazabicyclo[3.3.1]nonane compounds, process for their preparation and medicaments containing these compounds
08/24/2010CA2345445C A composition for the prevention and/or treatment of atherosclerosis
08/20/2010CA2655949A1 A method for treating hypercholesterolemic, hypertriglyceridemic, hyperlipidemic and/or dyslipidemic conditons and their related complications linked to metabolic disorders such as obesity and diabetes, using a crude plant extract from the genus tabernaemontana (peschiera), namely peschiera fuchsiaefolia, alone or combined with other therapeutics
08/19/2010WO2010093784A2 Modified virus vectors and methods of making and using the same
08/19/2010WO2010093771A1 Combination vegfr2 therapy with temozolomide
08/19/2010WO2010093629A1 Par-1 antagonism in fed or antacid-dosed patients
08/19/2010WO2010093627A2 Fibronectin type iii domain based scaffold compositions, methods and uses
08/19/2010WO2010093601A1 Novel sulfonic acid-containing thyromimetics, and methods for their use
08/19/2010WO2010093460A2 Particle size-structured parenteral dispersions
08/19/2010WO2010092941A1 Composition having vasodilation activity, process for producing same, and use of same
08/19/2010WO2010092811A1 Prophylactic or therapeutic agent for hypertension
08/19/2010WO2010092660A1 Inhibitor of casein kinase 1δ and casein kinase 1ε
08/19/2010WO2010092224A1 Biopolymer, implant comprising it and uses thereof
08/19/2010WO2010092015A1 Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
08/19/2010WO2010091488A1 Composition containing vegetable oil and resveratrol, method for producing same and nutraceuticals containing said composition
08/19/2010WO2010075347A3 Treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
08/19/2010WO2010075263A3 Compounds and methods for enhancing erythropoiesis
08/19/2010WO2010066028A8 3,4 - substituted piperidine derivatives as renin inhibitors
08/19/2010WO2010062557A3 Multimodal imaging of atherosclerotic plaque targeted to lox-1
08/19/2010WO2010056985A9 Treatment of proteinopathies using a farnesyl transferase inhibitor
08/19/2010WO2010054114A3 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
08/19/2010WO2010054113A3 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
08/19/2010WO2010054001A3 D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
08/19/2010WO2010049808A3 Chamomilla extract for the treatment of hypertension
08/19/2010WO2010044070A3 Synergistic composition for recovery and reduction of mild ischemic damage
08/19/2010WO2010026596A3 Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses
08/19/2010WO2009135581A3 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
08/19/2010US20100212036 Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
08/19/2010US20100210838 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity
08/19/2010US20100210734 Method of using calcitriol for treating intraocular diseases associated with angiogenesis
08/19/2010US20100210727 Hepoxilin analog enantiomers
08/19/2010US20100210726 Composition for promoting ketone body production
08/19/2010US20100210718 Synergistic anti-oxidant treatment for lipotoxicity and other metabolically related phenomena
08/19/2010US20100210713 Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
08/19/2010US20100210694 New no-donor aspirin derivatives
08/19/2010US20100210692 Methods of treatment using sirt modulators and compositions containing sirt1 modulators
08/19/2010US20100210685 Novel Substituted Indoles
08/19/2010US20100210671 Quinazolinone T-Type Calcium Channel Antagonists
08/19/2010US20100210667 Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists
08/19/2010US20100210666 Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy
08/19/2010US20100210660 Heterocyclic FXR Binding Compounds
08/19/2010US20100210658 Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
08/19/2010US20100210656 NOVEL sEH INHIBITORS AND THEIR USE
08/19/2010US20100210655 NOVEL sEH INHIBITORS AND THEIR USE
08/19/2010US20100210654 Novel p2y12 receptor antagonists
08/19/2010US20100210647 Indole compounds as an inhibitor of cellular necrosis
08/19/2010US20100210646 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
08/19/2010US20100210641 Organic Compounds
08/19/2010US20100210640 Benzamide derivatives, their preparation and uses in medicine thereof
08/19/2010US20100210637 Heteroaryloxy nitrogenous saturated heterocyclic derivative
08/19/2010US20100210635 Renin inhibitors
08/19/2010US20100210634 Certain Chemical Entities, Compositions and Methods
08/19/2010US20100210633 Carboxamide compounds and their use
08/19/2010US20100210631 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
08/19/2010US20100210628 NOVEL sEH INHIBITORS AND THEIR USE
08/19/2010US20100210627 Pyrazine compounds, their use and methods of preparation
08/19/2010US20100210622 Heterocyclic compounds and methods of use
08/19/2010US20100210620 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers
08/19/2010US20100210608 Therapeutic treatment
08/19/2010US20100210597 C21-Deoxy Ansamycin Derivatives as Antitumor Agents
08/19/2010US20100210593 Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
08/19/2010US20100210586 Pomegranate extracts, nutritional products containing them and their uses
08/19/2010US20100210579 Partial and full agonists of a1 adenosine receptors
08/19/2010US20100210572 Hydrolysate of crocin
08/19/2010US20100210568 Thyrotropin releasing hormone for therapeutic applications
08/19/2010US20100210565 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
08/19/2010US20100210559 Trap-14 as a therapeutic agent
08/19/2010US20100210556 Use of a peptide as a therapeutic agent
08/19/2010US20100210555 Use of a laminin peptide as a therapeutic agent
08/19/2010US20100210552 Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditions
08/19/2010US20100210539 Use of peptide ll-37 as a therapeutic agent
08/19/2010US20100210537 Use of a defensin peptide as a therapeutic agent
08/19/2010US20100210535 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof
08/19/2010US20100210530 Extracellular matrix compositions
08/19/2010US20100210525 Combined preparation of a thiazide diuretic and a loop diuretic
08/19/2010US20100210524 Novel estrogen receptor ligands